NVO Projected Dividend Yield
ADR/Novo-Nordisk AS ( NYSE : NVO )Novo-Nordisk is a healthcare company focuses on diabetes care. Co. is engaged in the discovery, development, manufacturing and marketing of pharmaceutical products and has two segments: diabetes and obesity care and biopharm. Co. has one diabetes product portfolios, including insulin, a portfolio of modern insulin and human insulin as well as a portfolio of GLP-1 receptor agonists administered both via subcutaneous injection and as a tablet. Co.'s first product to treat obesity is Saxenda®. Co.'s second obesity treatment product is Wegovy®. In addition, Co.'s marketed portfolio includes haemophilia and growth hormone therapies. 29 YEAR PERFORMANCE RESULTS |
NVO Dividend History Detail NVO Dividend News NVO Competitors News |
Year | Declaration Date | Ex-Dividend Date | Record Date | Payable Date | Dividend $ Amount |
2024 | N/A | Mar 22, 2024 | Mar 25, 2024 | Apr 02, 2024 | 0.6634 |
2024 Total: | 0.6634 | ||||
2023 | N/A | Aug 18, 2023 | Aug 21, 2023 | Aug 29, 2023 | 0.3124 |
2023 | N/A | Mar 24, 2023 | Mar 27, 2023 | Apr 04, 2023 | 0.4234 |
2023 Total: | 0.7358 | ||||
2022 | N/A | Aug 12, 2022 | Aug 15, 2022 | Aug 23, 2022 | 0.2034 |
2022 | N/A | Mar 25, 2022 | Mar 28, 2022 | Apr 05, 2022 | 0.3657 |
2022 Total: | 0.5691 | ||||
2021 | N/A | Aug 16, 2021 | Aug 17, 2021 | Aug 25, 2021 | 0.1934 |
2021 | N/A | Mar 26, 2021 | Mar 29, 2021 | Apr 07, 2021 | 0.3316 |
2021 Total: | 0.5249 | ||||
2020 | N/A | Aug 14, 2020 | Aug 17, 2020 | Aug 25, 2020 | 0.1840 |
2020 | N/A | Mar 27, 2020 | Mar 30, 2020 | Apr 07, 2020 | 0.2807 |
2020 Total: | 0.4646 | ||||
2019 | N/A | Aug 16, 2019 | Aug 19, 2019 | Aug 27, 2019 | 0.1575 |
2019 | N/A | Mar 22, 2019 | Mar 25, 2019 | Apr 02, 2019 | 0.2786 |
2019 Total: | 0.4361 |